Investigational drug · Phase 2
HDM2005
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diffuse Large B Cell Lymphoma (DLBCL).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HDM2005"
First trial start
2025
Jul 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HDM2005", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Large B Cell Lymphoma (DLBCL)
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HDM2005" as an intervention, largest first.
- A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid TumorRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06615193 · 111 participants (planned) · Start Aug 12, 2024 · Primary completion Jun 24, 2026
Drug: HDM2005 · For: Advanced Solid Tumors; Refractory Lymphoma; Relapsed Hematologic Malignancy
Sites: Zhengzhou, China; Suzhou, China; Xuzhou, China · 8 sites in all
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07124936 · 97 participants (planned) · Start Jul 30, 2025 · Primary completion Oct 26, 2027
Drug: HDM2005; Rituximab or Rituximab biosimilar and 5 more · For: Diffuse Large B Cell Lymphoma (DLBCL)
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 21 sites in all
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07004296 · 72 participants (planned) · Start May 29, 2025 · Primary completion Jul 1, 2027
Drug: HDM2005 · For: Advanced Solid Tumors
Sites: Shanghai, China
- HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell LymphomaNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07697339 · 40 participants (planned) · Start Jul 10, 2026 · Primary completion Aug 10, 2027
Drug: Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len; Rituximab plus lenalidomide and 2 more · For: Mantle Cell Lymphoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diffuse Large B Cell Lymphoma (DLBCL)
- Rondecabtagene autoleucelLYL314Phase 32 trials
Lyell Immunopharma, Inc. · Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Prizloncabtagene AutoleucelC-CAR039Phase 22 trials
AbelZeta Inc. · Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL)
- VTRU200Phase 21 trial
Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.